Endpoints News· Kyle LaHucik·· 3 小时前AI 评分67
Servier 15.5 亿美元引进的 Edgewise 药物 sevasemten 关键试验失败
Servier's $1.5B bet on Edgewise drug fails five months in
AI 导读
Servier 以 15.5 亿美元首付款从 Edgewise 引进的肌营养不良药物 sevasemten 在关键试验中失败，距交易完成仅五个月。Endpoints News 报道称该药物未能通过这项关键研究，原文其余内容需订阅后阅读。
正文 · 原文
The muscular dystrophy drug that Servier bought for $1.55 billion upfront has already failed its pivotal trial.
The drug, called sevasemten, failed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源：Endpoints News · endpoints.news